14.86MMarket Cap-0.89P/E (TTM)
1.1500High1.0800Low301.71KVolume1.1000Open1.0700Pre Close335.16KTurnover2.31%Turnover RatioLossP/E (Static)13.15MShares3.800052wk High1.98P/B14.78MFloat Cap0.580052wk Low--Dividend TTM13.08MShs Float347.0000Historical High--Div YieldTTM6.54%Amplitude0.5800Historical Low1.1100Avg Price1Lot Size
Hoth Therapeutics Stock Forum
HOTH's Cancer Breakthrough: Strategic Alliance Accelerates Novel HT-KIT Therapeutic Research
PR Newswire· 1 min ago
NEW YORK, Feb. 10, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company dedicated to developing innovative therapies for unmet medical needs, today announced its collaboration with OnTargetx R&D Inc. to advance research for its cancer-fighting therapeutic, HT-KIT. This immunohistochemistry study...
Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer Therapeutic
Monday, 10th February at 8:22 am
NEW YORK, Feb. 10, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company dedicated to developing innovative therapies for unmet medical needs, today announced its collaboration with OnTargetx R&D Inc. to advance research for its cancer-fighting therapeutic, HT-KIT. This immunohistochemi...
Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements
Friday, 24th January at 8:29 am
NEW YORK, Jan. 24, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) (the "Company" or "Hoth Therapeutics"), a biopharmaceutical company, today announced that it has received notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Nasdaq's minimum bid price requireme...
Hoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent Applications
Tuesday, 21st January at 8:29 am
IP will be used to pursue further indications for HT-001 Cancer Therapeutic
NEW YORK, Jan. 21, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, proudly announces advancements in its intellectual property portfolio through the acquisition and expansion of patent applications ...
ahem
No comment yet